OBINUTUZUMAB PLUS DHAP FOLLOWED BY AUTOLOGOUS STEM CELL...

Hematological Oncology 2019 / 06 Vol. 37

OBINUTUZUMAB PLUS DHAP FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) PLUS OBINUTUZUMAB MAINTENANCE PROVIDES A HIGH MRD RESPONSE RATE IN UNTREATED MCL PATIENTS. RESULTS OF LYMA-101 TRIAL, A LYSA GROUP STUDY

Le Gouill, S., Beldi-Ferchiou, A., Cacheux, V., Salles, G., Canioni, D., Bodet-Milin, C., Alcantara, M., Delwail, V., Gastinne, T., Thieblemont, C., Maisonneuve, H., Lamy de la Chapelle, T., Oberic, l
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
37
Language:
english
Journal:
Hematological Oncology
DOI:
10.1002/hon.14_2629
Date:
June, 2019
File:
PDF, 203 KB
english, 2019
Conversion to is in progress
Conversion to is failed